Long intergenic non-protein coding RNA 613 (LINC00613)

Long intergenic non-protein coding RNA 613 (LINC00613) is a human long non-coding RNA (lncRNA) gene, categorized as a non-protein-coding transcript[1][3][5]. It is not a receptor, enzyme, transporter, or classical therapeutic target, but instead acts as a regulatory RNA involved in cellular processes such as gene expression modulation, cell cycle regulation, metabolism, and tissue development[2]. LINC00613 has gained interest primarily for its association with cancer. Its lower expression is correlated with advanced tumor stage, increased proliferation, and poor prognosis—particularly in breast cancer, but also across a diverse set of tumor types[2]. Functional analyses suggest that LINC00613 negatively regulates the Wnt signaling pathway and cyclin D1 (CCND1) expression, thereby inhibiting cell cycle progression and potentially reducing tumor cell proliferation[2]. It also appears to influence tumor glycolysis and may affect immune cell infiltration in the tumor microenvironment[2]. LINC00613 is considered a prognostic biomarker rather than a direct therapeutic target, and there are currently no known drugs that interact directly with this lncRNA, nor mechanisms of action for drug targeting[2][5]. It is primarily of interest for its potential as a biomarker for disease outcome prediction, not for patient selection for targeted therapies[2]. No significant safety concerns or therapeutic challenges specific to LINC00613 have been reported in the literature[2][5].

Other names

RP11-782E2.1